NuVasive Company Profile (NASDAQ:NUVA)

About NuVasive (NASDAQ:NUVA)

NuVasive logoNuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:NUVA
  • CUSIP: 67070410
  • Web:
  • Market Cap: $3.62 billion
  • Outstanding Shares: 50,662,000
Average Prices:
  • 50 Day Moving Avg: $72.90
  • 200 Day Moving Avg: $70.34
  • 52 Week Range: $53.05 - $77.88
  • Trailing P/E Ratio: 75.08
  • Foreward P/E Ratio: 28.96
  • P/E Growth: 2.37
Sales & Book Value:
  • Annual Revenue: $996.83 million
  • Price / Sales: 3.64
  • Book Value: $13.69 per share
  • Price / Book: 5.23
  • EBIDTA: $222.39 million
  • Net Margins: 3.29%
  • Return on Equity: 12.26%
  • Return on Assets: 5.35%
  • Debt-to-Equity Ratio: 0.81%
  • Current Ratio: 2.37%
  • Quick Ratio: 1.51%
  • Average Volume: 574,024 shs.
  • Beta: 0.86
  • Short Ratio: 8.79

Frequently Asked Questions for NuVasive (NASDAQ:NUVA)

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Tuesday, April, 25th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.37 by $0.01. The company had revenue of $249.86 million for the quarter, compared to the consensus estimate of $250.52 million. NuVasive had a return on equity of 12.26% and a net margin of 3.29%. The firm's revenue was up 16.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.34 earnings per share. View NuVasive's Earnings History.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its FY17 earnings guidance on Tuesday, April, 25th. The company provided earnings per share (EPS) guidance of $2.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.02. The company issued revenue guidance of $1.065 billion, compared to the consensus revenue estimate of $1.07 billion.

Where is NuVasive's stock going? Where will NuVasive's stock price be in 2017?

12 brokerages have issued 12 month target prices for NuVasive's shares. Their predictions range from $57.00 to $85.00. On average, they expect NuVasive's stock price to reach $76.00 in the next year. View Analyst Ratings for NuVasive.

What are analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:

  • 1. According to Zacks Investment Research, "NuVasive exited the first quarter of 2017 on a mixed note, with earnings beating the Zacks Consensus Estimate and revenues in line with the mark. Per management, the low-margin Biotronic business impacted the quarter’s performance. However, the year-over-year improvement on the top-line front is on account of strong procedural growth in the U.S. as well as internationally. NuVasive’s strong momentum in the U.S. and international businesses in the first quarter raises optimism. We are also optimistic about the company’s recent progress in development of technologies and services for spine surgery. Meanwhile, the company has been trading below the broader Medical Products industry over the last three months. The stock’s valuation is also quite stretched. Further, currency headwind, pricing and reimbursement issues and competitive landscape are major downsides." (4/27/2017)
  • 2. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)

Who are some of NuVasive's key competitors?

Who owns NuVasive stock?

NuVasive's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.11%), GOLDMAN SACHS GROUP INC (7.90%), Champlain Investment Partners LLC (3.77%), State Street Corp (3.24%), Eagle Asset Management Inc. (2.82%) and Fisher Asset Management LLC (2.68%). Company insiders that own NuVasive stock include Gregory T Lucier, Jack R Blair, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles, Quentin S Blackford and Russell Powers. View Institutional Ownership Trends for NuVasive.

Who sold NuVasive stock? Who is selling NuVasive stock?

NuVasive's stock was sold by a variety of institutional investors in the last quarter, including Jana Partners LLC, American Century Companies Inc., UBS Group AG, Hood River Capital Management LLC, Eos Focused Equity Management L.P., Fisher Asset Management LLC, Ameriprise Financial Inc. and Jennison Associates LLC. Company insiders that have sold NuVasive stock in the last year include Jason Hannon, Lesley H Howe and Matthew Link. View Insider Buying and Selling for NuVasive.

Who bought NuVasive stock? Who is buying NuVasive stock?

NuVasive's stock was bought by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Victory Capital Management Inc., Wellington Management Group LLP, Vanguard Group Inc., Teachers Advisors LLC, Eagle Asset Management Inc., United Services Automobile Association and Blue Jay Capital Management LLC. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran and Patrick Miles. View Insider Buying and Selling for NuVasive.

How do I buy NuVasive stock?

Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NuVasive stock cost?

One share of NuVasive stock can currently be purchased for approximately $71.54.

Analyst Ratings

Consensus Ratings for NuVasive (NASDAQ:NUVA) (?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $76.00 (6.23% upside)

Analysts' Ratings History for NuVasive (NASDAQ:NUVA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Cowen and CompanyReiterated RatingOutperform$85.00LowView Rating Details
5/15/2017Royal Bank of CanadaReiterated RatingBuy$76.00LowView Rating Details
4/26/2017Canaccord GenuityReiterated RatingBuy$82.00 -> $84.00MediumView Rating Details
4/24/2017Barclays PLCBoost Price TargetOverweight$80.00 -> $82.00MediumView Rating Details
4/11/2017BMO Capital MarketsReiterated RatingBuy$82.00LowView Rating Details
2/16/2017Jefferies Group LLCReiterated RatingBuy$79.00 -> $84.00N/AView Rating Details
2/10/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
11/30/2016AegisInitiated CoverageBuy$72.00N/AView Rating Details
9/1/2016Piper Jaffray CompaniesReiterated RatingOverweight$70.00N/AView Rating Details
7/27/2016Brean CapitalBoost Price TargetBuy$60.00 -> $70.00N/AView Rating Details
7/13/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$55.00 -> $74.00N/AView Rating Details
6/7/2016Morgan StanleyReiterated RatingHold$57.00N/AView Rating Details
5/10/2016Leerink SwannReiterated RatingBuy$65.00N/AView Rating Details
12/11/2015Bank of America CorpUpgradeUnderperform -> Neutral$56.00N/AView Rating Details
7/29/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$48.00 -> $68.00N/AView Rating Details
6/3/2015Goldman Sachs Group IncDowngradeBuy -> Neutral$52.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for NuVasive (NASDAQ:NUVA)
Earnings by Quarter for NuVasive (NASDAQ:NUVA)
Earnings History by Quarter for NuVasive (NASDAQ:NUVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2017Q1 2017$0.37$0.38$250.52 million$249.86 millionViewN/AView Earnings Details
2/9/2017Q416$0.51$0.53$261.25 million$271.10 millionViewListenView Earnings Details
10/25/2016Q316$0.40$0.40$243.49 million$239.60 millionViewListenView Earnings Details
7/26/2016Q216$0.36$0.40$232.86 million$236.50 millionViewListenView Earnings Details
4/26/2016Q116$0.27$0.31$205.54 million$215.10 millionViewListenView Earnings Details
2/11/2016Q415$0.31$0.35$215.08 million$215.30 millionViewListenView Earnings Details
10/27/2015Q315$0.27$0.35$200.21 million$200.50 millionViewListenView Earnings Details
7/28/2015Q215$0.25$0.31$200.71 million$202.91 millionViewListenView Earnings Details
5/4/2015Q115$0.21$0.30$189.30 million$192.40 millionViewListenView Earnings Details
2/24/2015Q4$0.37$0.39$201.40 million$204.30 millionViewListenView Earnings Details
10/30/2014Q314$0.14$0.09$179.30 million$189.90 millionViewListenView Earnings Details
7/29/2014Q214$0.25$0.28$177.50 million$190.70 millionViewListenView Earnings Details
4/29/2014Q114$0.13$0.29$171.30 million$177.50 millionViewListenView Earnings Details
3/3/2014Q413$0.32$0.37$181.24 million$190.80 millionViewListenView Earnings Details
10/29/2013Q313$0.24$0.39$158.30 million$169.20 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.23$0.20$161.67 million$165.70 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.22$0.26$157.34 million$159.50 millionViewListenView Earnings Details
2/26/2013Q4 2012$0.21$0.34$156.35 million$165.80 millionViewListenView Earnings Details
10/24/2012$0.21$0.23ViewN/AView Earnings Details
7/25/2012$0.23$0.27ViewN/AView Earnings Details
4/30/2012$0.18$0.20ViewN/AView Earnings Details
2/22/2012$0.22$0.27ViewN/AView Earnings Details
10/27/2011$0.24$0.26ViewN/AView Earnings Details
7/25/2011$0.28$0.30ViewN/AView Earnings Details
5/5/2011$0.19$0.24ViewN/AView Earnings Details
2/23/2011$0.42$0.46ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NuVasive (NASDAQ:NUVA)
2017 EPS Consensus Estimate: $2.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.37$0.39$0.38
Q2 20173$0.44$0.48$0.46
Q3 20173$0.50$0.55$0.52
Q4 20173$0.64$0.68$0.66
Q2 20181$0.61$0.61$0.61
Q3 20181$0.60$0.60$0.60
(Data provided by Zacks Investment Research)


Dividend History for NuVasive (NASDAQ:NUVA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NuVasive (NASDAQ:NUVA)
Insider Ownership Percentage: 4.70%
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)
Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/8/2017Jason HannonInsiderSell24,840$74.22$1,843,624.80View SEC Filing  
2/14/2017Lesley H. HoweDirectorSell6,049$73.26$443,149.74View SEC Filing  
12/12/2016Matthew LinkInsiderSell10,303$67.99$700,500.97View SEC Filing  
11/4/2016Michael D OhalleranDirectorBuy4,200$58.26$244,692.00View SEC Filing  
11/2/2016Patrick MilesDirectorBuy16,967$58.97$1,000,543.99View SEC Filing  
11/1/2016Patrick MilesDirectorBuy16,667$59.00$983,353.00View SEC Filing  
10/31/2016Joan StafslienEVPBuy5,000$59.68$298,400.00View SEC Filing  
10/31/2016Michael D OhalleranDirectorBuy4,205$59.47$250,071.35View SEC Filing  
8/23/2016Jason HannonEVPSell2,625$64.80$170,100.00View SEC Filing  
8/2/2016Jason HannonEVPSell11,184$62.70$701,236.80View SEC Filing  
8/2/2016Lesley H. HoweDirectorSell3,602$62.44$224,908.88View SEC Filing  
7/20/2016Jason HannonEVPSell2,920$62.80$183,376.00View SEC Filing  
6/16/2016Jason HannonEVPSell14,534$57.57$836,722.38View SEC Filing  
1/6/2016Patrick MilesCOOSell10,723$54.03$579,363.69View SEC Filing  
12/16/2015Patrick MilesCOOSell9,127$52.56$479,715.12View SEC Filing  
12/7/2015Quentin S BlackfordCFOSell15,000$51.10$766,500.00View SEC Filing  
12/3/2015Patrick MilesCOOSell5,873$52.51$308,391.23View SEC Filing  
11/2/2015Patrick MilesCOOSell15,000$48.12$721,800.00View SEC Filing  
10/5/2015Matthew LinkinsiderSell1,714$50.72$86,934.08View SEC Filing  
10/3/2015Quentin S BlackfordCFOSell5,000$36.30$181,500.00View SEC Filing  
10/1/2015Patrick MilesCOOSell15,000$48.10$721,500.00View SEC Filing  
9/8/2015Russell PowersEVPSell5,806$51.64$299,821.84View SEC Filing  
9/2/2015Jason HannonEVPSell11,962$52.02$622,263.24View SEC Filing  
9/1/2015Patrick MilesCOOSell15,000$52.03$780,450.00View SEC Filing  
8/31/2015Patrick MilesCOOSell15,000$53.34$800,100.00View SEC Filing  
7/20/2015Jason HannonEVPSell15,000$49.60$744,000.00View SEC Filing  
6/15/2015Gregory T LucierCEOBuy4,491$49.49$222,259.59View SEC Filing  
6/12/2015Gregory T LucierCEOBuy8,000$50.10$400,800.00View SEC Filing  
6/10/2015Gregory T LucierCEOBuy10,000$49.10$491,000.00View SEC Filing  
6/8/2015Gregory T LucierCEOBuy10,000$49.26$492,600.00View SEC Filing  
6/4/2015Gregory T LucierCEOBuy10,000$49.71$497,100.00View SEC Filing  
6/2/2015Gregory T LucierCEOBuy8,000$49.96$399,680.00View SEC Filing  
6/2/2015Patrick MilesCOOSell4,194$49.47$207,477.18View SEC Filing  
5/29/2015Jack R BlairDirectorSell3,703$50.16$185,742.48View SEC Filing  
5/28/2015Gregory T LucierCEOBuy34,000$49.25$1,674,500.00View SEC Filing  
5/28/2015Russell PowersEVPSell8,042$49.00$394,058.00View SEC Filing  
5/19/2015Patrick MilesCOOSell15,000$47.52$712,800.00View SEC Filing  
5/1/2015Russell PowersEVPSell11,881$45.21$537,140.01View SEC Filing  
4/24/2015Russell PowersEVPSell3,888$44.07$171,344.16View SEC Filing  
3/13/2015Patrick MilesCOOSell7,920$45.52$360,518.40View SEC Filing  
3/9/2015Alexis V LukianovCEOSell5,313$44.82$238,128.66View SEC Filing  
3/3/2015Matthew LinkInsiderSell7,500$44.46$333,450.00View SEC Filing  
3/2/2015Jason HannonEVPSell5,085$45.06$229,130.10View SEC Filing  
2/9/2015Alexis V LukianovCEOSell5,454$46.10$251,429.40View SEC Filing  
2/5/2015Matthew LinkInsiderSell4,078$45.77$186,650.06View SEC Filing  
2/3/2015Patrick MilesCOOSell15,000$45.53$682,950.00View SEC Filing  
1/28/2015Keith ValentineCOOSell6,970$46.96$327,311.20View SEC Filing  
1/12/2015Alexis V LukianovCEOSell7,452$49.69$370,289.88View SEC Filing  
1/5/2015Jason HannonEVPSell12,117$46.82$567,317.94View SEC Filing  
1/5/2015Patrick MilesInsiderSell15,000$46.61$699,150.00View SEC Filing  
12/30/2014Jason HannonEVPSell15,000$47.63$714,450.00View SEC Filing  
12/29/2014Jason HannonEVPSell3,146$47.57$149,655.22View SEC Filing  
12/24/2014Patrick MilesInsiderSell15,000$47.52$712,800.00View SEC Filing  
12/19/2014Keith ValentineCOOSell5,893$47.78$281,567.54View SEC Filing  
12/1/2014Keith ValentineCOOSell2,500$43.66$109,150.00View SEC Filing  
11/19/2014Keith ValentineCOOSell5,582$43.32$241,812.24View SEC Filing  
11/19/2014Quentin S BlackfordCFOSell7,698$43.41$334,170.18View SEC Filing  
11/7/2014Alexis V LukianovCEOSell25,000$41.40$1,035,000.00View SEC Filing  
11/3/2014Keith ValentineCOOSell2,500$40.61$101,525.00View SEC Filing  
10/2/2014Keith ValentineCOOSell2,500$35.00$87,500.00View SEC Filing  
9/2/2014Keith ValentineCOOSell2,500$35.14$87,850.00View SEC Filing  
8/1/2014Keith ValentineCOOSell2,500$37.11$92,775.00View SEC Filing  
8/1/2014Michael LambertCFOSell4,010$37.11$148,811.10View SEC Filing  
7/30/2014Jason HannonEVPSell5,000$39.00$195,000.00View SEC Filing  
7/10/2014Russell PowersEVPSell3,200$33.43$106,976.00View SEC Filing  
7/1/2014Keith ValentineCOOSell2,500$35.65$89,125.00View SEC Filing  
7/1/2014Michael LambertCFOSell23,225$35.48$824,023.00View SEC Filing  
6/20/2014Keith ValentineCOOSell5,000$35.00$175,000.00View SEC Filing  
6/20/2014Russell PowersEVPSell9,526$35.00$333,410.00View SEC Filing  
5/5/2014Robert HuntDirectorSell20,000$34.25$685,000.00View SEC Filing  
5/2/2014Michael LambertCFOSell13,096$33.07$433,084.72View SEC Filing  
4/1/2014Keith ValentineCOOSell2,500$38.41$96,025.00View SEC Filing  
3/11/2014Peter FarrellDirectorSell48,000$36.88$1,770,240.00View SEC Filing  
1/21/2014Jason HannonEVPSell10,095$36.60$369,477.00View SEC Filing  
1/16/2014Keith ValentineCOOSell20,000$37.96$759,200.00View SEC Filing  
1/7/2014Alexis LukianovCEOSell34,217$34.29$1,173,300.93View SEC Filing  
1/7/2014Craig HunsakerSVPSell4,980$35.00$174,300.00View SEC Filing  
12/30/2013Craig HunsakerSVPSell4,275$32.10$137,227.50View SEC Filing  
12/23/2013Michael LambertCFOSell17,091$32.49$555,286.59View SEC Filing  
11/7/2013Alexis LukianovCEOSell5,000$31.45$157,250.00View SEC Filing  
10/30/2013Jason HannonEVPSell2,334$28.90$67,452.60View SEC Filing  
10/30/2013Patrick MilesInsiderSell21,223$31.10$660,035.30View SEC Filing  
10/28/2013Patrick MilesInsiderSell7,331$25.72$188,553.32View SEC Filing  
10/21/2013Russell PowersVPSell12,500$25.39$317,375.00View SEC Filing  
10/11/2013Jason HannonEVPSell1,000$26.00$26,000.00View SEC Filing  
10/7/2013Jason HannonEVPSell8,705$23.99$208,832.95View SEC Filing  
10/7/2013Michael LambertCFOSell15,442$24.04$371,225.68View SEC Filing  
8/6/2013Richard Treharne IIIDirectorBuy2,000$23.26$46,520.00View SEC Filing  
7/12/2013Craig E HunsakerSVPSell2,000$27.00$54,000.00View SEC Filing  
7/8/2013Alexis V LukianovCEOSell5,000$25.74$128,700.00View SEC Filing  
7/1/2013Keith ValentineCOOSell1,698$25.00$42,450.00View SEC Filing  
5/13/2013Alexis V LukianovCEOSell7,500$22.71$170,325.00View SEC Filing  
5/8/2013Peter Michael LeddyDirectorBuy2,400$22.24$53,376.00View SEC Filing  
5/7/2013Alexis V LukianovCEOSell12,500$22.11$276,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NuVasive (NASDAQ:NUVA)
Latest Headlines for NuVasive (NASDAQ:NUVA)
DateHeadline logoNuVasive Announces Educational Initiatives In Support Of Spine's Fastest Growing Spinal Deformity Portfolio - PR Newswire (press release) - May 23 at 10:08 AM logoForm 4 NUVASIVE INC For: May 18 Filed by: Norwalk Leslie V - - May 23 at 10:08 AM logoNuVasive Announces Educational Initiatives In Support Of Spine's Fastest Growing Spinal Deformity Portfolio - May 22 at 9:50 AM logoJoint Reconstruction Devices Market Size Worth $30.4 Billion by 2025: Grand View Research, Inc. - May 19 at 11:42 AM logoNuVasive, Inc. (NUVA) Earns Outperform Rating from Cowen and Company - May 15 at 12:42 PM logoNuVasive To Present At Bank of America Merrill Lynch 2017 Global Healthcare Conference - May 9 at 6:33 PM logoETFs with exposure to NuVasive, Inc. : May 8, 2017 - May 8 at 6:23 PM logoNuVasive, Inc. (NUVA) Upgraded by TheStreet to "B" - May 6 at 11:52 PM logo$0.45 EPS Expected for NuVasive, Inc. (NUVA) This Quarter - May 5 at 8:50 AM logoNuVasive Announces Sponsorship Of EPOSNA 2017 And Launches New Monthly Pediatric Spinal Deformity Podcast - PR Newswire (press release) - May 5 at 12:03 AM logoNuVasive (NUVA) Earns Daily Media Sentiment Rating of 0.20 - May 4 at 1:10 AM logoNuVasive Announces Sponsorship Of EPOSNA 2017 And Launches New Monthly Pediatric Spinal Deformity Podcast - May 2 at 4:43 PM logoNuVasive, Inc. (NUVA) Receives Consensus Recommendation of "Buy" from Analysts - May 1 at 10:32 PM logoNuVasive (NUVA) Getting Somewhat Favorable News Coverage, Report Finds - April 30 at 6:05 PM logoFY2018 Earnings Estimate for NuVasive, Inc. (NUVA) Issued By Jefferies Group - April 28 at 11:30 PM logoETFs with exposure to NuVasive, Inc. : April 28, 2017 - April 28 at 7:57 PM logoPositive Press Coverage Likely to Affect NuVasive (NUVA) Share Price - April 28 at 12:56 AM logoNuVasive, Inc. :NUVA-US: Earnings Analysis: Q1, 2017 By the Numbers : April 27, 2017 - April 27 at 7:26 PM logoNuVasive, Inc. (NUVA) Lifted to Hold at Zacks Investment Research - April 27 at 1:16 PM logoQ2 2017 Earnings Estimate for NuVasive, Inc. Issued By Jefferies Group (NUVA) - April 27 at 8:36 AM logoNuVasive, Inc. (NUVA) to Post Q2 2017 Earnings of $0.44 Per Share, Leerink Swann Forecasts - April 27 at 8:19 AM
News IconBRIEF-NuVasive reports Q1 gaap earnings per share $0.22 - April 26 at 6:21 PM logoNuVasive (NUVA) Q1 2017 Results - Earnings Call Transcript - April 26 at 6:21 PM logoNuVasive Straightens Up With Solid Growth - April 26 at 6:21 PM logoEdited Transcript of NUVA earnings conference call or presentation 25-Apr-17 8:30pm GMT - April 26 at 6:21 PM logoBuy The Dip In NuVasive Shares, Says Canaccord Genuity - April 26 at 3:21 PM logoNuVasive, Inc. (NUVA) Receives "Buy" Rating from Canaccord Genuity - April 26 at 2:42 PM logoNuVasive, Inc. (NUVA) Announces Quarterly Earnings Results - April 25 at 10:06 PM logoNuVasive, Inc. (NUVA) Releases FY17 Earnings Guidance - April 25 at 7:02 PM logoNuVasive, Inc. Bottom Line Climbs 17% In Q1 - Nasdaq - April 25 at 6:08 PM logoNuVasive Announces First Quarter 2017 Financial Results - April 25 at 6:08 PM logoNuVasive beats 1Q profit forecasts - April 25 at 6:08 PM logoHere's how much NuVasive's 5 highest-paid executives earned - Dayton Business Journal - April 25 at 8:07 AM logoHere’s how much NuVasive’s 5 highest-paid executives earned - April 25 at 8:07 AM logoBarclays PLC Reiterates Overweight Rating for NuVasive, Inc. (NUVA) - April 24 at 10:22 PM logoLawsuit for Investors in NASDAQ:NUVA Shares against Directors of NuVasive, Inc Announced by Shareholders ... - Yahoo Finance - April 24 at 2:17 PM logoLawsuit for Investors in NASDAQ:NUVA Shares against Directors of NuVasive, Inc Announced by Shareholders Foundation - April 24 at 2:17 PM logoNuVasive (NUVA) Receiving Somewhat Critical News Coverage, Report Shows - April 24 at 1:58 PM logoNuVasive, Inc. (NUVA) Short Interest Up 0.3% in March - April 21 at 8:45 PM logoNuVasive Unveils New Trauma Portfolio And Virtual Reality Simulation At AANS 2017 - Yahoo Finance - April 21 at 6:49 PM logoNuVasive Launches New Spinal Trauma Portfolio - PR Newswire (press release) - April 21 at 6:49 PM logoNuVasive, Inc. – Value Analysis (NASDAQ:NUVA) : April 21, 2017 - April 21 at 6:49 PM logoNuVasive (NUVA) Receives Media Sentiment Score of -0.08 - April 21 at 5:55 PM logoNuVasive (NUVA) Q1 Earnings: Disappointment in the Cards? - April 21 at 9:27 AM logoNuVasive launching products to hit $100M market - April 20 at 7:00 PM logoNuVasive Unveils New Trauma Portfolio And Virtual Reality Simulation At AANS 2017 - April 20 at 7:00 PM logoNuVasive, Inc. breached its 50 day moving average in a Bullish Manner : NUVA-US : April 20, 2017 - April 20 at 9:12 AM logoNuVasive Launches New Spinal Trauma Portfolio - April 19 at 6:58 PM logoNuVasive (NUVA) Receives Daily News Impact Score of 0.31 - April 18 at 7:33 PM logoNuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $250.74 Million - April 16 at 9:40 AM


NuVasive (NUVA) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff